The Flt3 ligand ( Flt3 -L ) manifests antitumor activity, presumably due to its capacity to recruit dendritic cells and cause their proliferation. To assess whether local production of Flt3 -L can mediate a ''distant bystander'' effect, murine B4B8 squamous cell carcinoma cells were transfected with a plasmid encoding a secretory form of Flt3 -L to produce B4B8FL cells. Similarly, B4B8FL and B4B8 cells were transfected with herpes simplex virus thymidine kinase ( HSVTK ) to produce B4B8TK and B4B8FL / TK cells, which should be sensitive to ganciclovir ( GCV ), to know whether the effects of Flt3 -L and HSVTK / GCV would be synergistic. To test for a distant bystander effect in vivo, B4B8FL, B4B8TK, and B4B8FL / TK cells were injected subcutaneously into the left flank of syngeneic Balb / c mice, and naïve B4B8 cells were injected into the right flank. The formation of tumors derived from B4B8FL and B4B8FL / TK cells was significantly delayed in both flanks compared with naïve B4B8 and B4B8TK cells. Growth of B4B8TK tumors in the ipsilateral flank was retarded following GCV treatment, but in contrast to B4B8FL and B4B8FL / TK cells, no distant bystander effect in the contralateral flank was observed. Immunohistochemistry showed lymphocytic infiltrates in both flanks of the B4B8FL and B4B8FL / TK groups. The data indicate that in these cells, local secretion of Flt3 -L is sufficient to evoke a distant bystander effect but that expression of HSVTK, even after GCV administration, is not. Furthermore, the combination of local Flt3 -L and HSVTK production, together with GCV administration, does not enhance the distant bystander effect produced by Flt3 -L alone.
A promising strategy for cancer gene therapy is the augmentation of tumor immunity by introducing vectors that express cytokines, costimulatory molecules, or antigen-presenting molecules into tumor cells. The most common approach has been to manipulate tumor cells so that they ectopically express cytokines such as IL -2, IL -4, TNF, GM -CSF, and IFN -g. These studies 1, 2 have been sufficiently promising as to encourage investigators to optimize combinations of cytokines to stimulate potential antitumor responses. The coexpression of two 3 -5 or three 6, 7 cytokines often shows an enhanced antitumor response compared with that of single cytokine. However, optimal combinations that induce complete and permanent tumor regression remain elusive.
A complementary cancer gene therapy strategy involves the introduction of a ''suicide gene'' encoding a prodrugconverting enzyme, followed by the administration of the appropriate prodrug. This strategy selectively targets cells that express the prodrug -converting enzyme. The herpes simplex virus thymidine kinase (HSVTK) gene is a prototypic suicide gene, which effectively phosphorylates the guanosine analog ganciclovir (GCV ) to its monophosphate form ( GCV-MP ). The GCV-MP can be further phosphorylated to its cytotoxic triphosphate form by endogenous cellular kinases. 8 An important advantage to this approach is that the activated GCV in HSVTK -expressing cells can be passed to nontransfected neighboring cells to produce a local bystander killing effect, 9 -13 a feature that is desirable for achieving effective therapeutic responses against cancer.
The Flt3 ligand ( Flt3 -L ) is a member of a small family of cytokines that affect growth, survival, and/ or differentiation of cells in the hematopoietic lineage 14, 15 by selective activation of their tyrosine kinase receptors. Flt3 -L can be expressed as either a type I transmembrane protein or as a secreted, soluble protein. 16 Both forms have a growthstimulatory effect on dendritic cells (DCs ), and appear capable of recruiting and inducing proliferation of CD11c + DCs in vivo. 17, 18 Because of its capacity to recruit and activate DCs, several investigators have used transgenic cells expressing Flt3 -L or have directly administered recombinant Flt3 -L in preclinical and clinical studies with varying degrees of success. 19 -21 Squamous cell carcinoma of the head and neck (HNSCC ) has high morbidity and mortality and is of major concern worldwide. HNSCC is frequently refractory to chemotherapy and can recur after surgery. 22 Significantly, despite the emergence of new therapeutic approaches, survival rates have shown little or no improvement. 23 Therefore, the need to explore new and novel strategies for HNSCC is obvious. Several laboratories have utilized adenoviral vectors to deliver genes encoding HSVTK, alone or in combination with cytokines, to cells of head and neck carcinoma origin. 24, 25 Transduction of tumor cells with HSVTK can produce a local bystander effect resulting in the killing of adjacent tumor cells. 26, 27 However, we and others have shown that expression of HSVTK in tumor followed by GCV administration can also produce a distant bystander effect whereby tumors at a site distant from the site of HSVTK expression undergo regression or retardation of growth. 26,28 -31 As Flt3 -L recruits and stimulates DCs, we reasoned that ectopic expression of Flt3 -L might enhance the effect of HSVTK and GCV administration, and produce a more robust distant bystander effect. To this end, cells from a murine SCC cell line ( B4B8 ), derived from a Balb /c mouse, were transfected to express either a murine, secretable Flt3 -L, HSVTK, or both. To test the hypothesis, naïve or genetically modified cells were injected subcutaneously in syngeneic Balb /c mice to determine whether either or both modifications in combination might confer immunity to B4B8 tumors locally or at a distance.
Materials and methods

Cell culture
Murine B4B8 cells are squamous carcinoma cells of Balb / c origin. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM ) containing 10% fetal bovine serum (FBS ), penicillin ( Sigma, St. Louis, MO ), and streptomycin (Sigma ). The B4B8 cells were treated with BM -Cyclin ( Boehringer Mannheim, Indianapolis, IN ), an antibiotic cocktail to prevent mycoplasma contamination.
Medium and cell extracts were tested for mycoplasma using a PCR kit ( Stratagene, La Jolla, CA ). The Baf3 /cells, a kind gift from Dr. Seiji Fukuda (Indiana University ), were maintained in RPMI medium containing 10% FBS and 100 pg /mL recombinant murine IL -3. The PA317 packaging cells carrying the HSVTK were maintained in DMEM with high glucose containing 10% FBS.
pcDNA3 / Flt3 -L construction, transfection, and HSVTK infection
The secreted murine Flt3 -L cDNA was cloned from total Balb/c spleen RNA by RT-PCR using the primers 5 0 -TCC 
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Flt3 -ligand mediated antitumor response J Dong et al CCG GCA GAG ATG A and 3 0 -CTG GCT GAG TCA ACG ACG ATG CA. The PCR -derived Flt3 -L was subcloned using the TA cloning system (Invitrogen, Carlsbad, CA ), and further subcloned into the HindIII and XhoI sites of pcDNA3. The B4B8 cells were transfected with the pcDNA3 /Flt3 -L vector using Effectene Transfection Reagent (Qiagen ) and selected for G418 resistance. Flt3 -L production and secretion into medium by transfected cells were assessed by ELISA ( R&D Systems ), and its activity was monitored by the capacity of conditioned medium to induce growth of Baf3 cells. A pooled population of B4B8 cells that secrete high levels of Flt3 -L was designated as B4B8FL cells and was further infected using supernatant from PA317 /TK producer cells in the presence of 8 g/mL polybrene. After 10 days of puromycin selection, these cells were again tested for Flt3 -L secretion and for GCV sensitivity in medium containing 20 M GCV. The cells expressing both Flt3 -L and TK were designated B4B8FL/ TK. In addition to the B4B8FL and B4B8 FL /TK cells, control B4B8 cells expressing TK alone (B4B8TK ), neo ( B4B8neo), and GFP (B4B8GFP ) were constructed as described above. B4B8neo and B4B8GFP vectors were also established as control vectors.
Northern and Western blot analyses
Total cellular RNA was isolated from cell pellets and 20 g of RNA was fractioned on a 1% agarose gel, transferred to nylon membrane (Fisher ), and hybridized with 32 P -labeled Flt3 -L cDNA. The cDNA was radiolabeled by end labeling ( Stratagene ), and hybridization was monitored by autoradiography. As a loading control, the membrane was stripped and rehybridized with a b -actin 32 P -labeled probe. HSVTK protein was detected by Western blot, using 50 g of cell lysate protein and the Bio -Rad DC assay (Bio -Rad, Hercules, CA ). Cell lysate proteins were separated by 8% SDS -PAGE and transferred to a nylon membrane. After blocking with 5% nonfat milk, the membrane was incubated with a rabbit polyclonal anti -HSVTK antibody (gift from Dr Richard Drake) for 30 minutes, followed by incubation with antigoat HRP polyclonal antibody for another 30 minutes. The reactive bands were detected with Western Blot Luminal Regent (Cat no. sc -2048; Santa Cruz Biotechnology ). As a loading control, the membrane was stripped and rechallenged with a mouse monoclonal anti-b -tubulin antibody (Sigma).
Production of Flt3 -L
Flt3 -L secretion by transfected cells was analyzed by the capacity of conditioned medium to stimulate growth of Baf3 cells. Proliferation of Baf3 cells was measured by the MTT assay (4,5 -dimethylthia 201 -2 -yl)-2,5-diphenytetrazolium bromide ( Sigma ). Baf3 cells were seeded in 96 -well plates at 1000 cells /well (50 L volume ) in triplicate. Conditioned medium from different pools of transfected cells expressing Flt3 -L was added to a final volume of 150 L, and after 3 days, 20 L of MTT (5 mg /mL ) was added. The plates were incubated at 5% CO 2 , 378C for an additional 4 hours, and 100 L of 0.04 N HCl in isopropanol was added and thoroughly mixed. The plate was read on a micro-ELISA reader using a test wavelength of 570 nm and a reference wavelength of 630 nm.
As confirmation, Flt3 -L secretion was also measured by a murine Flt3 -L ELISA kit ( R&D Systems ), according to manufacturer's instruction. Cells were trypsinized, counted, and added to wells of six -well plates at a density of lÂ10 
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In vitro bystander effect
The in vitro bystander effect was measured by coculturing B4B8TK or B4B8FL /TK cells with B4B8 cells at different ratios. B4B8FL cells were also modified to express GFP. Cultures were treated with GCV ranging from 0.1 to 100 M for 2 -4 days. Viability and relative cell numbers in each of the cocultures were measured by MTT analysis, as described.
As confirmation, the survival of B4B8GFP cells was monitored by fluorescence microscopy.
Animal studies and distant bystander effect
Sets of eight mice were injected subcutaneously in the left flank with either 5Â10 6 B4B8TK, B4B8FL, or B4B8FL /TK cells, and the same number of naïve B4B8 cells was injected in the right flank of the same mice. Mice carrying tumors that express HSVTK were injected intraperitoneally with GCV ( 50 mg /kg weight ) twice daily, or left untreated as controls.
Additional controls included subcutaneous injection of mice with cells carrying only the vector expressing the neo drug resistance marker. The tumor size in each flank was measured on every third day and tumor volume was estimated by the product of the width squared times 1 /2 the length ( 0.5LÂW 2 ).
Histological and immunohistochemistry analysis
One half of each tumor was fixed in paraformaldehyde and embedded in paraffin for standard histology. 
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Statistics
Tumor volumes were statistically analyzed using analysis of variance for multiple comparisons. Paired analysis between two groups was performed using the Student's t test. A P value <.05 was considered to indicate a significant difference between groups.
Results
Flt3 -L expression by B4B8FL and B4B8FL / TK cells
To establish B4B8FL cell lines that stably express high levels of the secretable form of Flt3 -L, cells were transfected with pcDNA3 /Flt3 -L and selected in G418. Expression of Flt3 -L in drug -resistant cells was first analyzed by RT-PCR, followed by Northern and Western blots. The results for pooled G418 -resistant cells are presented in Figure 1 . The B4B8FL cells clearly produce Flt3 -L message, in contrast to untransfected cells (Fig 1 ) ; however, the Flt3 -L protein, a secreted protein, was not detected by Western blot in cell extracts (data not shown ). To verify that B4B8FL cells produced biologically active Flt3 -L, conditioned medium from two separate pools of B4B8FL cells were tested for their capacity to stimulate growth of Baf3 cells. Baf3 is a pre B -cell line that expresses the Flt3 receptor and that is responsive to both human and murine Flt3 -L. 32 -34 The relative growth -promoting activity of the two B4B8FL pools, compared with parental B4B8 cells, shown in Figure  2A , is 6 -to 7 -fold higher than background. These cultures of pooled cells were derived from two separate wells from which conditioned medium supported growth of Baf3 cells more effectively than medium containing 100 ng /mL recombinant Flt3 -L.
Aliquots of these cells were infected with retroviruses containing HSVTK, and infected cells were selected with GCV. Following infection with HSVTK -expressing retroviruses, the B4B8 cells expressing Flt3 -L (B4B8 FL / TK ) 
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Flt3 -ligand mediated antitumor response J Dong et al retained good Flt3 -L biological activity ( Fig 2A ) and Flt3 -L protein based on ELISA analysis (Fig 2B ) . The relative amounts of Flt3 -L secreted into the medium in a 24-hour period were 16.2± 0.1 and 13.6 ± 0.3 ng /mL for F4B8FL and B48B8 FL /TK cells, respectively ( Fig 2B ) . These values were derived from a standard curve describing the effect of increasing concentrations of recombinant Flt3 -L on Baf3 growth ( data not shown ). ) and B4B8FL / TK mice. Magnification is Â400 for A -G and Â1200 for H and I.
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Expression of HSVTK in B4B8TK and B4B8FL / tk cells
Two independent sets of pooled B4B8TK and B4B8FL /TK cells were analyzed by Western blot for TK expression. As seen in Figure 3 , significant but variable amounts of TK were expressed. Parental B4B8 and B4B8 neo cells produced no HSVTK protein ( data not shown). The biologic activity of the expressed HSVTK, and its capacity to produce an in vitro bystander effect in both cases, were assessed by cocultivating B4B8TK and B4B8FL / TK cells with naïve B4B8 cells followed by GCV administration. Cells expressing TK were mixed with naïve B4B8 cells at ratios ranging from 0% to 20% and treated with increasing concentrations of GCV. Both B4B8TK ( Fig 4A ) and B4B8FL / TK cells (Fig 4B ) manifested a strong in vitro bystander effect at 10 M GCV, whereas parental cells that do not express HSVTK remained unaffected by GCV administration. To verify cooperative killing by GCV, B4B8FL /TK cells were cocultured with B4B8GFP cells in the presence of 10 M GCV, and viability of the B4B8GFP cells was monitored by GFP fluorescence. By 96 hours, no viable GFP + cells were observed (Fig 5) .
Antitumor effects of HSVTK and Flt3 -L
The growth rates of B4B8FL, B4B8TK, and B4B8FL /TK cells in culture were determined and found to be essentially the same as that of parental B4B8 cells (data not shown ). Thus, ectopic expression of Flt3 -L or HSVTK did not affect the growth of the cells in vitro. The relative growth of these cell lines as tumors was assessed by subcutaneous inoculation, and their effect on the growth of tumors at a distant site was also examined. To this end, B4B8FL, B4B8TK, and B4B8FL /TK cells were injected individually into the left flank of mice and unmodified, naïve B4B8 cells were injected subcutaneously into the contralateral flank. Tumor size was measured as a function of time. The B4B8 and B4B8TK tumors grew with the same kinetics as parental B4B8 cells injected in one flank only, whereas B4B8FL and B4B8FL /TK tumors grew more slowly ( P <.0015 ) ( Fig 6) . B4B8 tumors in the contralateral flank grew with wild -type kinetics when either B4B8 (control ) or B4B8TK tumors were present in the ipsilateral flank, even following GCV administration. However, their growth was retarded when B4B8FL or B4B8FL /TK was present in the ipsilateral flank ( P <.034 and P < .0021, respectively ). These data indicate that expression of Flt -3 ligand can produce a distant bystander effect. In the absence of GCV, all animals injected with B4B8, B4B8neo, and B4B8TK cells developed tumors with similar kinetics (P < .05) (Fig 6 ) . Following GCV treatment, B4B8TK tumors showed significantly reduced growth ( P <.0025 ) and B4B8TK /FL cells showed significant tumor regression ( P <.006 ) in the ipsilateral flank ( Fig 7A ) . However, naïve B4B8 tumors in the contralateral flanks of mice that harbored HSVTK -containing tumors in their ipsilateral were not affected in their growth ( Fig 7B ) , indicating that tumors derived from B4B8 cells expressing HSVTK did not manifest a distant bystander effect following GCV administration. This result is in contrast to B4B8FL and B4B8FL /TK cells, which showed a distant bystander effect without the need for further treatment.
Immunohistochemical detection of CD11c
+ cells at the tumor site
Tumor from both flanks of each group was stained with hematoxylin and eosin. Tumors from both ipsilateral and contralateral flanks of the B4B8FL and B4B8FL /TK groups showed significant lymphocyte infiltration and tumor necrosis. In contrast, there was no significant cell infiltration in either flank of B4B8TK tumor or in control group (data not shown ). To assess the identity of these infiltrating cells, tumors from both flanks of mice with B4B8TK, B4B8FL, and B4B8FL /TK tumors were stained with antibody to CD4, CD8 ( data not shown), and CD11c. The CD11c antibody recognizes activated T cells as well as DCs. Following immunostaining with CD11c antibody (Fig 8 ) , significant numbers of CD11c + were observed surrounding tumor-associated vessels in tumors from both flanks of B4B8FL and B4B8FL /TK mice. There was no significant difference in staining in tumors from the ipsilateral and contralateral flanks. In addition, there were numerous isolated CD11c
+ cells that had a clear stellate morphology characteristic of DCs, but only in the ipsilateral flanks of mice with B4B8FL and B4B8FL / TK tumors ( Fig 8 ) . These CD11c + cells were not observed in the contralateral flanks of these mice, or in either flank of mice with B4B8 TK tumors with or without GCV treatment.
Discussion
Many anticancer gene therapy strategies rely on genetic modification of tumor cells, rendering them susceptible to spontaneous or drug induced cell death. Two approaches that have been used include transduction of tumor cells with ''suicide'' genes and transduction of genes that encode cytokines or that otherwise modulate immune responses. A salient feature of both approaches is that not all cells in a tumor need to be transduced to achieve a broad antitumor response. Such a bystander effect has been observed in vitro 9, 35, 36 and in vivo. 26, 37, 38 Transduction of tumor cells with HSVTK, using adenoviral 25, 37, 38 or retroviral 26, 36, 39 vectors followed by administration of GCV, has produced encouraging results. In cultured cells, there is often a robust bystander effect that is mediated by the transfer of cytotoxic phosphorylated GCV products to nontransduced neighboring cells by passage through gap junctions. 9, 40 This local bystander effect requires physical contact between affected cells. In vivo, a local bystander effect may be operative but likely is not the predominant mechanism by which nontransduced tumor cells are killed. When HSVTK -expressing human squamous carcinoma tumor cells were injected subcutaneously in one flank and naïve tumors cells that do not express HSVTK were injected in the contralateral flank, tumors in both flanks regressed or showed diminished growth rates following GCV administration, 26 indicative of a systemic rather than exclusively local response. Similar results have been observed in a chemically induced rat mammary tumor model 41 and in a liver tumor model in which tumors comprised of a mixture of HSVTK -expressing and nonexpressing cells in one liver lobe, as well as naïve tumor cells in another liver lobe, both regressing following
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Flt3 -ligand mediated antitumor response J Dong et al GCV administration. 30 This systematic antitumor effect has been ascribed to an antitumor immune response and may involve the production of cytokines such as GM -CSF and IL -12 42 that may mediate such a response. Stimulation of an antitumor immune response and recruitment of immune cells to the site of a tumor have been the basis of numerous antitumor strategies. 43 These approaches have included isolating and purifying DCs and pulsing them ex vivo with either purified tumor antigen or with tumor cell lysate. 44, 45 When reintroduced into the host, the pulsed DCs, which serve as potent antigen -presenting cells, can elicit an effective antitumor immune response. The biological activity of Flt3 -L includes the capacity to recruit DCs, causing them to proliferate. This characteristic has been exploited in clinical trials involving the direct administration of recombinant hFlt -3 ligand. 18 -21 One objective of the experiments described in this report was to test whether the use of the HSVTK /GCV strategy, when coupled with an approach designed to recruit DCs to the tumor site, would act in an additive or synergistic fashion to evoke an enhanced immune antitumor response. As described above, the B4B8 cells appeared to be refractory to the HSVTK /GCV approach in vivo, even though B4B8TK cells were sensitive to GCV in vitro and manifested a bystander effect. However, B4B8 cells did show sensitivity to Flt -3 ligand expression in vivo and manifested a distant bystander effect. B4B8 cells expressing Flt -3 ligand were retarded in the onset of tumor growth and grew more slowly than their unmodified B4B8 cell counterparts. Naïve B4B8 cells, introduced into the contralateral flank of mice with cells expressing Flt3 -L in the ipsilateral flank, also displayed delayed onset of tumor development and retarded tumor growth, characteristic of a distant bystander effect. Tumors in the ipsilateral flank showed clear recruitment of DCs to the site of the tumor, consistent with the predicted in vivo activity of Flt3 -L. Also apparent was an infiltration of CD4 + and CD8 + T cells. In contrast, DCs were not detected in the contralateral tumors, suggesting that an antitumor response was established locally at the ipsilateral tumor in response to Flt3 -L, and was sufficient to affect tumors at distant sites. It should also be noted that in a murine breast cancer model, Flt3 -L stimulated an effective antitumor effect mediated, in part, by natural killer cells. 46 It is clear that local production of Flt3 -L in this experimental model can produce an antitumor response locally and at a distance. However, it is unclear why mice with tumors expressing HSVTK and treated with GCV in this model do not manifest a distant bystander effect. It is conceivable that the concentration of GCV at the tumor site is insufficient to elicit enough tumor cell killing to produce a distant bystander effect. Alternatively, these tumor cells may be very weakly antigenic so that distant tumors may evade immune surveillance. The method of tumor cell transduction may also play a role in the degree of response because differences in extent of lymphocyte infiltration have been reported between liposome adenoviral and retroviral methods of transduction in an HSVTK / GCV rat glioblastoma model. 47 However, regardless of the explanation, the failure of one approach that has been successful in other models illustrates the need for the development of multiple new strategies that can be used in combination, or in the event that one of the strategies is ineffective.
